These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 8874972)

  • 21. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
    Kempers J; MacLaren DM
    J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
    [No Abstract]   [Full Text] [Related]  

  • 27. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.
    Coleman K; Griffin DR; Page JW; Upshon PA
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1580-7. PubMed ID: 2817854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
    Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics].
    Sawicka-Grzelak A; Rokosz A
    Med Dosw Mikrobiol; 1998; 50(1-2):69-76. PubMed ID: 9857616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
    Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.